Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB.

Nat Med. 1996 May;2(5):561-6.


Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H.

Clin Cancer Res. 1998 Jul;4(7):1661-72.


The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

Deininger MW, Goldman JM, Lydon N, Melo JV.

Blood. 1997 Nov 1;90(9):3691-8.


Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.


CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ.

Blood. 1997 Dec 15;90(12):4947-52.


In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C.

J Natl Cancer Inst. 1999 Jan 20;91(2):163-8.


Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.

Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Pioltelli P, Pogliani E, Corneo G, Formelli F, D'Incalci M.

J Natl Cancer Inst. 2000 Oct 18;92(20):1641-50.


Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB.

Blood Cells Mol Dis. 1997 Dec;23(3):380-94.


Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.

Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, Savoldo B, Cilloni D, Tabilio A, Levitzki A, Rizzoli V.

Blood. 1999 Jun 1;93(11):3973-82.


In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.

Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M.

Cancer. 2002 May 15;94(10):2653-62.


[Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].

Toga W, Kondo M, Tokoro A.

Nihon Yakurigaku Zasshi. 2003 Feb;121(2):119-28. Review. Japanese.


[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].

Usui N.

Rinsho Byori. 2004 Feb;52(2):136-44. Review. Japanese.


Chronic myelogenous leukaemia--new therapeutic principles.

O'Dwyer ME, Druker BJ.

J Intern Med. 2001 Jul;250(1):3-9. Review.


Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.


Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.

Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW, Atadja P, Bhalla K.

Blood. 2006 Jul 15;108(2):645-52. Epub 2006 Mar 14.


ARG tyrosine kinase activity is inhibited by STI571.

Okuda K, Weisberg E, Gilliland DG, Griffin JD.

Blood. 2001 Apr 15;97(8):2440-8.

Supplemental Content

Support Center